330 related articles for article (PubMed ID: 31359231)
1. Predictive Impact of Peripheral Blood Markers and C-Reactive Protein in Nivolumab Therapy for Metastatic Renal Cell Carcinoma.
Ishihara H; Tachibana H; Takagi T; Kondo T; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Target Oncol; 2019 Aug; 14(4):453-463. PubMed ID: 31359231
[TBL] [Abstract][Full Text] [Related]
2. C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Jan; 25(1):135-144. PubMed ID: 31512006
[TBL] [Abstract][Full Text] [Related]
3. C-reactive protein and neutrophil-lymphocyte ratio are prognostic in metastatic clear-cell renal cell carcinoma patients treated with nivolumab.
Roussel E; Kinget L; Verbiest A; Debruyne PR; Baldewijns M; Van Poppel H; Albersen M; Beuselinck B
Urol Oncol; 2021 Apr; 39(4):239.e17-239.e25. PubMed ID: 33485762
[TBL] [Abstract][Full Text] [Related]
4. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
5. The neutrophil-lymphocyte ratio has a role in predicting the effectiveness of nivolumab in Japanese patients with metastatic renal cell carcinoma: a multi-institutional retrospective study.
Nishiyama N; Hirobe M; Kikushima T; Matsuki M; Takahashi A; Yanase M; Ichimatsu K; Egawa M; Hayashi N; Negishi T; Masumori N; Kitamura H
BMC Urol; 2020 Jul; 20(1):110. PubMed ID: 32711491
[TBL] [Abstract][Full Text] [Related]
6. Predictive impact of an early change in serum C-reactive protein levels in nivolumab therapy for metastatic renal cell carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
Urol Oncol; 2020 May; 38(5):526-532. PubMed ID: 31864934
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
[TBL] [Abstract][Full Text] [Related]
8. C-reactive protein at 1 month after treatment of nivolumab as a predictive marker of efficacy in advanced renal cell carcinoma.
Noguchi G; Nakaigawa N; Umemoto S; Kobayashi K; Shibata Y; Tsutsumi S; Yasui M; Ohtake S; Suzuki T; Osaka K; Muraoka K; Hasumi H; Kondo K; Igarashi Y; Sasada T; Kishida T; Yao M
Cancer Chemother Pharmacol; 2020 Jul; 86(1):75-85. PubMed ID: 32537714
[TBL] [Abstract][Full Text] [Related]
9. Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab.
Bilen MA; Dutcher GMA; Liu Y; Ravindranathan D; Kissick HT; Carthon BC; Kucuk O; Harris WB; Master VA
Clin Genitourin Cancer; 2018 Jun; 16(3):e563-e575. PubMed ID: 29402706
[TBL] [Abstract][Full Text] [Related]
10. Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.
Zahoor H; Barata PC; Jia X; Martin A; Allman KD; Wood LS; Gilligan TD; Grivas P; Ornstein MC; Garcia JA; Rini BI
J Immunother Cancer; 2018 Oct; 6(1):107. PubMed ID: 30333065
[TBL] [Abstract][Full Text] [Related]
11. Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab.
Fukuda S; Saito K; Yasuda Y; Kijima T; Yoshida S; Yokoyama M; Ishioka J; Matsuoka Y; Kageyama Y; Fujii Y
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33602695
[TBL] [Abstract][Full Text] [Related]
12. Effect of Systemic Inflammation on Survival in Patients With Metastatic Renal Cell Carcinoma Receiving Second-line Molecular-targeted Therapy.
Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
Clin Genitourin Cancer; 2017 Aug; 15(4):495-501. PubMed ID: 28363437
[TBL] [Abstract][Full Text] [Related]
13. Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab.
Ueda K; Suekane S; Kurose H; Ogasawara N; Hiroshige T; Chikui K; Uemura K; Nakiri M; Nishihara K; Matsuo M; Igawa T
Jpn J Clin Oncol; 2022 Feb; 52(2):179-186. PubMed ID: 34607361
[TBL] [Abstract][Full Text] [Related]
14. Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab.
De Giorgi U; Procopio G; Giannarelli D; Sabbatini R; Bearz A; Buti S; Basso U; Mitterer M; Ortega C; Bidoli P; Ferraù F; Crinò L; Frassoldati A; Marchetti P; Mini E; Scoppola A; Verusio C; Fornarini G; Cartenì G; Caserta C; Sternberg CN
Clin Cancer Res; 2019 Jul; 25(13):3839-3846. PubMed ID: 30967420
[TBL] [Abstract][Full Text] [Related]
15. Hematological predictive markers for recurrent or metastatic squamous cell carcinomas of the head and neck treated with nivolumab: A multicenter study of 88 patients.
Matsuki T; Okamoto I; Fushimi C; Sawabe M; Kawakita D; Sato H; Tsukahara K; Kondo T; Okada T; Tada Y; Miura K; Omura G; Yamashita T
Cancer Med; 2020 Jul; 9(14):5015-5024. PubMed ID: 32441463
[TBL] [Abstract][Full Text] [Related]
16. Correlation between the magnitude of best tumor response and patient survival in nivolumab therapy for metastatic renal cell carcinoma.
Ishihara H; Takagi T; Kondo T; Tachibana H; Fukuda H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
Med Oncol; 2019 Mar; 36(4):35. PubMed ID: 30879157
[TBL] [Abstract][Full Text] [Related]
17. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, and C-reactive Protein as New and Simple Prognostic Factors in Patients With Metastatic Renal Cell Cancer Treated With Tyrosine Kinase Inhibitors: A Systemic Review and Meta-analysis.
Semeniuk-Wojtaś A; Lubas A; Stec R; Syryło T; Niemczyk S; Szczylik C
Clin Genitourin Cancer; 2018 Jun; 16(3):e685-e693. PubMed ID: 29454639
[TBL] [Abstract][Full Text] [Related]
18. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study.
Russo A; Russano M; Franchina T; Migliorino MR; Aprile G; Mansueto G; Berruti A; Falcone A; Aieta M; Gelibter A; Russo A; Barni S; Maio M; Martelli O; Pantano F; Iacono D; Calvetti L; Quadrini S; Roca E; Vasile E; Imperatori M; Occhipinti M; Galvano A; Petrelli F; Calabrò L; Pasquini G; Intagliata S; Ricciardi GRR; Tonini G; Santini D; Adamo V
Adv Ther; 2020 Mar; 37(3):1145-1155. PubMed ID: 32002809
[TBL] [Abstract][Full Text] [Related]
19. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
Simonaggio A; Elaidi R; Fournier L; Fabre E; Ferrari V; Borchiellini D; Thouvenin J; Barthelemy P; Thibault C; Tartour E; Oudard S; Vano YA
Cancer Immunol Immunother; 2020 Dec; 69(12):2513-2522. PubMed ID: 32561968
[TBL] [Abstract][Full Text] [Related]
20. Identifying Early Predictive Markers for Immune-Related Adverse Events in Nivolumab-Treated Patients with Renal Cell Carcinoma and Gastric Cancer.
Takada S; Murooka H; Tahatsu K; Yanase M; Umehara K; Hashishita H; Toru H; Satoru M; Sagawa T; Fujikawa K; Sato H; Mino K
Asian Pac J Cancer Prev; 2022 Feb; 23(2):695-701. PubMed ID: 35225483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]